Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.36 |
| ▸ | MET | P08581 | 3/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100631 | 0.90 | ACHE (0.36) | LRRK2 | |
| SCHEMBL10100705 | 0.90 | LRRK2 (0.41) | LRRK2MAPK1METFGFR1FGFR2 | |
| SCHEMBL10100381 | 0.89 | MAP4K3 (0.42) | LRRK2METFGFR1FGFR2FGFR3 | |
| SCHEMBL2356833 | 0.88 | LRRK2 (0.39) | LRRK2MAPK1METFGFR1FGFR2 | |
| SCHEMBL2358758 | 0.88 | LRRK2 (0.39) | LRRK2MAPK1METFGFR1FGFR2 | |
| Hydrochloric Acid SCHEMBL2357336 | 0.88 | LRRK2 (0.39) | LRRK2MAPK1METFGFR1FGFR2 | |
| SCHEMBL10100634 | 0.88 | EPHX2 (0.42) | MAPK1 | |
| SCHEMBL10100638 | 0.87 | LRRK2 (0.38) | LRRK2MAPK1METFGFR1FGFR2 | |
| SCHEMBL10100641 | 0.86 | CHEK1 (0.42) | LRRK2MAPK1METFGFR1FGFR2 | |
| SCHEMBL2365320 | 0.83 | MAPK1 (0.40) | LRRK2MAPK1METMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2010048131-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | LRRK2 856/4885MAPK1 357/4885MET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.